Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about BCL2L1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
BCL2L1 is a gene implicated in neurodegeneration research. Key relationships include: associated with, expressed in, regulates. Associated with ALS, Aging, Als. Connected to 302 entities in the SciDEX knowledge graph.
| Gene Symbol | BCL2L1 |
| Chromosome | 20q11.21 |
| Protein Type | Signaling Protein |
| Target Class | Signaling Protein |
| Function | is a gene located on chromosome 20q11.21 that encodes a member of the BCL-2 family of proteins |
| Mechanism of Action | Small molecule inhibitor of anti-apoptotic protein function |
| Primary Expression | Cerebral cortex, Hippocampus, Substantia nigra, Spinal cord |
| Druggability | High (0.80) |
| Clinical Stage | Approved |
| Pathways | Akt, Nf-Κb, Pi3K, Toll-Like Receptor |
| UniProt ID | Q07817 |
| NCBI Gene ID | 598 |
| Ensembl ID | ENSG00000171552 |
| OMIM | 300040 |
| GeneCards | BCL2L1 |
| Human Protein Atlas | BCL2L1 |
| Associated Diseases | ALS, Cancer, Carcinoma, Cardiovascular, Ischemia |
| Known Drugs/Compounds | Abt263, ABT263, rapamycin |
| Interactions | AKT, IL1B, PI3K, MTOR, CASP3, TBK1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Senescent Microglia Resolution via Maresins-Senoly |
| KG Connections | 568 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
flowchart TD
FOXO["FOXO<br/>Transcription Factor"] --|"activates"|--> BCL2L1["BCL2L1<br/>(Bcl-xL)<br/>Anti-apoptotic Protein"]
BCL2L1 --|"inhibits"|--> Apoptosis["Cellular Apoptosis<br/>Programmed Cell Death"]
BCL2L1 --|"regulates"|--> Mitochondria["Mitochondrial<br/>Membrane Stability"]
Apoptosis --|"leads to"|--> Neurodegeneration["Neurodegeneration<br/>Neural Cell Loss"]
Mitochondria --|"dysfunction causes"|--> Neurodegeneration
BCL2L1 --|"regulates"|--> Alzheimer["Alzheimer's Disease<br/>Cognitive Decline"]
BCL2L1 --|"inhibits"|--> ALS["Amyotrophic Lateral<br/>Sclerosis (ALS)"]
BCL2L1 --|"associated with"|--> Parkinson["Parkinson's Disease<br/>Motor Dysfunction"]
BCL2L1 --|"associated with"|--> MS["Multiple Sclerosis<br/>Demyelination"]
BCL2L1 --|"regulates"|--> Inflammation["Neuroinflammation<br/>Immune Response"]
BCL2L1 --|"regulates"|--> Aging["Cellular Aging<br/>Senescence"]
BCL2L1 --|"associated with"|--> Ischemia["Cerebral Ischemia<br/>Oxygen Deprivation"]
Inflammation --|"contributes to"|--> Neurodegeneration
Aging --|"promotes"|--> Neurodegeneration
Ischemia --|"triggers"|--> Apoptosis
BCL2L1 --|"biomarker for"|--> Senescence["Cellular Senescence<br/>Age-related Decline"]
style BCL2L1 fill:#006494
style FOXO fill:#4a1a6b
style Apoptosis fill:#ef5350
style Neurodegeneration fill:#5d4400
style Mitochondria fill:#1b5e20
style Inflammation fill:#ef5350
style Aging fill:#5d4400
style Senescence fill:#5d4400| Target | Relation | Type | Str |
|---|---|---|---|
| Tumor Cell Survival | involved_in | process | 0.93 |
| EGFR-TKI Resistance | contributes_to | phenotype | 0.92 |
| Egfr-Tki Resistance | upregulates | phenotype | 0.90 |
| Tumor Cell | expressed_in | cell_type | 0.90 |
| Tumor Cell Survival | promotes | process | 0.90 |
| Egfr-Tki Resistance | contributes_to | phenotype | 0.90 |
| Apoptosis | inhibits | process | 0.88 |
| Biomarker For Egfr-Tki Resistance | biomarker_for | biomarker | 0.85 |
| Senescent Cells | involved_in | cell_type | 0.85 |
| Apoptosis | involved_in | process | 0.85 |
| SY-1365 Sensitivity | associated_with | phenotype | 0.80 |
| apoptosis pathway | participates_in | pathway | 0.80 |
| BCL-xL | encodes | protein | 0.80 |
| unfolded protein response | participates_in | pathway | 0.70 |
| APOPTOSIS | upregulates | process | 0.70 |
| neurodegeneration | associated_with | disease | 0.66 |
| Carcinoma | expressed_in | disease | 0.65 |
| Ms | expressed_in | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Als | expressed_in | disease | 0.65 |
| Cancer | associated_with | disease | 0.65 |
| Neurodegeneration | associated_with | disease | 0.65 |
| Cardiovascular | associated_with | disease | 0.65 |
| Ischemia | associated_with | disease | 0.65 |
| Parkinson | associated_with | disease | 0.65 |
| Ms | associated_with | disease | 0.65 |
| Inflammation | regulates | disease | 0.65 |
| Senescence | biomarker_for | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Aging | regulates | disease | 0.65 |
| Alzheimer | regulates | disease | 0.65 |
| Obesity | regulates | disease | 0.65 |
| Diabetes | regulates | disease | 0.65 |
| Cancer | expressed_in | disease | 0.65 |
| Leukemia | inhibits | disease | 0.65 |
| Tumor | inhibits | disease | 0.65 |
| Als | inhibits | disease | 0.65 |
| Als | associated_with | disease | 0.65 |
| Carcinoma | associated_with | disease | 0.65 |
| Cancer | regulates | disease | 0.65 |
| Cardiovascular | regulates | disease | 0.65 |
| Neurodegeneration | regulates | disease | 0.65 |
| Leukemia | regulates | disease | 0.65 |
| Tumor | regulates | disease | 0.65 |
| Als | therapeutic_target | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| Cancer | therapeutic_target | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| Source | Relation | Type | Str |
|---|---|---|---|
| ABT263 | inhibits | drug | 0.95 |
| Abt263 | inhibits | drug | 0.90 |
| EGFR-TKI Treatment | upregulates | drug | 0.90 |
| h-3f02f222 | targets_gene | hypothesis | 0.90 |
| PD-1 | downregulates | protein | 0.82 |
| h-3f02f222 | targets | hypothesis | 0.80 |
| TP53 | downregulates | gene | 0.80 |
| PRV_gM | binds | protein | 0.80 |
| FOXO | activates | protein | 0.80 |
| IL1B | activates | gene | 0.60 |
| ULK1 | associated_with | gene | 0.60 |
| BCL2 | associated_with | gene | 0.60 |
| RAB9A | associated_with | gene | 0.60 |
| FAS | regulates | gene | 0.60 |
| MMP1 | regulates | gene | 0.60 |
| BAK1 | biomarker_for | gene | 0.60 |
| MCL1 | expressed_in | gene | 0.60 |
| BCL2 | expressed_in | gene | 0.60 |
| PI3K | activates | gene | 0.60 |
| EGFR | expressed_in | gene | 0.60 |
| GABARAP | associated_with | gene | 0.60 |
| PIK3C3 | associated_with | gene | 0.60 |
| MAP1LC3B | associated_with | gene | 0.60 |
| TFEB | associated_with | gene | 0.60 |
| MTOR | associated_with | gene | 0.60 |
| AMBRA1 | associated_with | gene | 0.60 |
| CTSD | associated_with | gene | 0.60 |
| HDAC6 | associated_with | gene | 0.60 |
| LAMP2 | associated_with | gene | 0.60 |
| UVRAG | associated_with | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| MAPK3 | therapeutic_target | gene | 0.60 |
| BCL2 | regulates | gene | 0.60 |
| TP53 | regulates | gene | 0.60 |
| TLR4 | regulates | gene | 0.60 |
| PI3K | regulates | gene | 0.60 |
| TNF | regulates | gene | 0.60 |
| CASP9 | regulates | gene | 0.60 |
| CASP8 | regulates | gene | 0.60 |
| AKT | regulates | gene | 0.60 |
| STAT3 | regulates | gene | 0.60 |
| JUN | regulates | gene | 0.60 |
| JAK2 | therapeutic_target | gene | 0.60 |
| HBB | expressed_in | gene | 0.60 |
| ESR1 | associated_with | gene | 0.60 |
| PSEN2 | associated_with | gene | 0.60 |
| ESR2 | associated_with | gene | 0.60 |
| SOX9 | associated_with | gene | 0.60 |
| VDAC2 | associated_with | gene | 0.60 |
| WDR45 | associated_with | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Senescent Microglia Resolution via Maresins-Senolytics Combi | 0.552 | neurodegeneration | Neuroinflammation resolution mechanisms |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-04 | 0 hypotheses
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.552
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the S [PMID:37738560] | Justice JN, Leng XI, LeBrasseur NK, Tchk | J Gerontol A Biol Sci Med Sci | 2024 | 1 |
| Sex differences in autophagy-mediated diseases: toward precision medicine. [PMID:32264724] | Shang D, Wang L, Klionsky DJ, Cheng H, Z | Autophagy | 2021 | 1 |
| Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populatio [PMID:33144684] | He D, Wang D, Lu P, Yang N, Xue Z, Zhu X | Oncogene | 2021 | 1 |
| Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells [PMID:26657143] | Chang J, Wang Y, Shao L, Laberge RM, Dem | Nat Med | 2016 | 1 |
| The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. [PMID:25754370] | Zhu Y, Tchkonia T, Pirtskhalava T, Gower | Aging Cell | 2015 | 1 |
| Senolytic elimination of therapy-induced senescent cells by ABT-263 improves che [PMID:41423036] | Zhang D, Zhu J, Zou R, Zhang H, Yu BP, L | Biochemical pharmacology | 2026 | 0 |
| Comprehensive assessment of the genomic stability of human induced pluripotent s [PMID:41877289] | Zhang K, Na T, Jia C, Yuan X, Guo M, Yan | Stem cell research & therapy | 2026 | 0 |
| Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Leng [PMID:41589352] | Elsner C, Epasto LM, Cieren A, Gendreizi | Chembiochem : a European journ | 2026 | 0 |
| Exploring the key molecular mechanisms and immune microenvironment of oxidative [PMID:41591671] | Cai Z, Li J, Li T, Peng Q | Discover oncology | 2026 | 0 |
| Navitoclax acts synergistically with irradiation to induce apoptosis in preclini [PMID:41430412] | Vardon A, Haston S, Hamdi H, Cooksley G, | Scientific reports | 2025 | 0 |
| Combination of senolytic and pro-resolving mediator shows synergistic benefit in [PMID:synthetic_19] | Unknown | Nat Aging | 2024 | 0 |
| Senolytic treatment diminishes microglia and decreases severity of experimental [PMID:39487537] | Drake SS, Zaman A, Gianfelice C, Hua EM, | Journal of neuroinflammation | 2024 | 0 |
| CSF markers of microglial senescence predict cognitive decline in Alzheimer's di [PMID:synthetic_20] | Unknown | Ann Neurol | 2023 | 0 |
| ABT-263 treatment reduces senescent microglia and improves cognition in APP/PS1 [PMID:synthetic_18] | Unknown | Neurobiol Aging | 2023 | 0 |
| Senescent microglia accumulate in Alzheimer's disease brains and drive neuroinfl [PMID:synthetic_16] | Unknown | Nature | 2023 | 0 |
| Maresin 1 reprograms microglia from pro-inflammatory to phagocytic phenotype via [PMID:synthetic_17] | Unknown | Cell | 2022 | 0 |
| Senescent cells provide beneficial functions in tissue repair and immune surveil [PMID:synthetic_21] | Unknown | Nat Rev Immunol | 2022 | 0 |
| ABT-263 causes dose-limiting thrombocytopenia in cancer trials via BCL-xL inhibi [PMID:synthetic_22] | Unknown | J Clin Oncol | 2020 | 0 |
| The Beclin 1 network regulates autophagy and apoptosis. [PMID:21311563] | Kang R, Zeh HJ, Lotze MT, Tang D | Cell death and differentiation | 2011 | 0 |
| The landscape of somatic copy-number alteration across human cancers. [PMID:20164920] | Beroukhim R, Mermel CH, Porter D, Wei G, | Nature | 2010 | 0 |